

Loratadine for the Prevention of G-CSF-related Bone Pain

NCT05421416

Status	RECRUITING
Phase	Phase 2
Sponsor	AHS Cancer Control Alberta
Enrollment	78 participants

Key Eligibility Criteria

Inclusion (7)

- A histologically or cytologically documented lymphoma or multiple myeloma
- Next line of therapy is autologous stem cell transplant
- Adult e 18 years old.
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.
- Life expectancy of at least 12 weeks.
- ... and 2 more (see full listing online)

Exclusion (4)

- Hypersensitivity or intolerance to antihistamines
- Use of antihistamines within two days prior to the study period, excepting the use of single dose antihistamines during chemotherapy or blood transfusion protocols.
- Recent use of G-CSF or pegfilgrastim defined as within 12 weeks of study accrual.
- New and continued regular use of analgesics within the four days prior to the first dose of G-CSF

Locations (1 total)

Cross Cancer Institute, Edmonton, Alberta, Canada